Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for Centralized Cardiac Safety Services for Select Pharmaceutical Clients
Spaulding Clinical Research has agreed to offer ECG services using the new Spaulding webECGTM Diagnostic ECG Management system for late stage clinical trials through Blinded Diagnostics. This web-based solution includes the Spaulding Model 1000iQ, a hand-held diagnostic 12-lead electrocardiograph designed to provide an easy-to-use, cost-effective, diagnostic assessment, while centralizing all data on a web-based system that allows for immediate access to study data globally. The multi-year collaboration assigns Blinded Diagnostics as a business development resource for a select group of pharmaceutical companies.
“We are very pleased with the relationship that we have built with Blinded Diagnostics. They are a knowledgeable and professional organization and will represent Spaulding’s unique service offerings well. We are confident in their ability to deliver customer-focused solutions to this select group of pharmaceutical companies,” states Kevin Geno, VP of Sales and Marketing for Spaulding Clinical Research.
“The Spaulding Model 1000iQ Electrocardiograph is an innovative and effective point of care 12-lead ECG device for use in clinical trials…” states Steve Karuppan, CEO of Blinded Diagnostics, “and we are particularly impressed by the Spaulding webECG data storage capability, analysis solutions and connectivity features for use in centralizing cardiac safety data from phase II-IV global trials.”
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
